Myfortic Dosage/Direction for Use

Treatment with Myfortic should be initiated and maintained by appropriately qualified transplant specialists.
The recommended dose is 720 mg administered twice daily (1,440 mg daily dose). This dose of mycophenolate sodium corresponds to 1 g mycophenolate mofetil administered twice daily (2 g daily dose) in terms of mycophenolic acid (MPA) content.
For additional information about the corresponding therapeutic doses of mycophenolate sodium and mycophenolate mofetil, see Pharmacology: Pharmacokinetics under Actions and Precautions.
In de novo patients, Myfortic should be initiated within 72 hours following transplantation.
Myfortic can be taken with or without food. Patients may select either option but must adhere to their selected option (see Pharmacology: Pharmacokinetics under Actions).
In order to retain the integrity of the enteric coating, Myfortic tablets should not be crushed.
Where crushing of Myfortic tablets is necessary, avoid inhalation of the powder or direct contact of the powder with skin or mucous membrane. If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water. This is due to the teratogenic effects of mycophenolate.
Paediatric population and adolescents: Insufficient data are available to support the efficacy and safety of Myfortic in children and adolescents. Limited pharmacokinetic data are available for paediatric renal transplant patients (see Pharmacology: Pharmacokinetics under Actions).
Older people: The recommended dose in elderly patients is 720 mg twice daily.
Patients with renal impairment: In patients experiencing delayed renal graft function post-operatively, no dose adjustments are needed (see Pharmacology: Pharmacokinetics under Actions).
Patients with severe renal impairment (glomerular filtration rate <25 ml·min^-1·1.73 m^-2) should be carefully monitored and the daily dose of Myfortic should not exceed 1,440 mg.
Patients with hepatic impairment: No dose adjustments are needed for renal transplant patients with severe hepatic impairment.
Treatment during rejection episodes: Renal transplant rejection does not lead to changes in mycophenolic acid (MPA) pharmacokinetics; dosage modification or interruption of Myfortic is not required.